MediPharm Labs Responds to Dissident Shareholder's Filing

About this update from Medipharm Labs Corp.

[{"type":"text","content":"\n\n\n\n MediPharm Labs Responds to Dissident Shareholder's Filing\n \n\n /* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n \n\n\n\n\n\n Canada NewsWire\n \n\n\n\n\n\n TORONTO\n \n\n ,\n \n\n May 8, 2025\n \n\n /CNW/ - MediPharm Labs Corp. (TSX: LABS) (\"MediPharm\" or the \"Company\"), a pharmaceutical company specialized in precision-based cannabinoids, is aware of the dissident proxy circular filed on\n \n May 7, 2025\n \n (the \"Dissident Circular\") by Apollo Technology Capital Corporation (\"Apollo\").\n \n\n\n\n\n\n\n\n\n The Dissident Circular outlines Apollo's intention to nominate six individuals for election to MediPharm's board of directors (\"Board\") at the Company's upcoming Annual and Special Meeting of Shareholders, scheduled for\n \n June 16, 2025\n \n .\n \n\n While our full response will be delivered in the coming days, we believe it is important to highlight several immediate concerns regarding Apollo's filing:\n \n\n\n\n No viable plan:\n \n Apollo has offered no concrete strategy to create sustainable value for shareholders — only broad criticisms without substance or actionable solutions.\n \n\n\n\n\n Questionable leadership and track record:\n \n The Board has significant concerns about Apollo's leadership, particularly the checkered history and lack of proven success of its lead dissident,\n \n Regan McGee\n \n , and certain of its proposed nominees.\n \n\n\n\n\n Meritless and Unspecified Allegations:\n \n The allegations of breach of fiduciary duty by directors of the Company are void of detail and without merit. The Company rejects these allegations in the strongest possible terms and cautions shareholders about the falsity of these assertions.\n \n\n\n\n\n Procedural non-compliance:\n \n Most notably, Apollo's advance notice\n \n fails to comply\n \n with MediPharm's advance notice bylaw and does not contain information that could be material to a reasonable shareholder's understanding of the independence or lack thereof of the proposed nominees. MediPharm has formally notified Apollo's legal counsel of these deficiencies, as required by the By-L...

More updates from Medipharm Labs Corp.